NASDAQ: DRTSAlpha Tau Medical Ltd Stock
$2.57+0.04 (+1.58%)
Updated Apr 17, 2025
DRTS Price
$2.57
Fair Value Price
N/A
Market Cap
$180.88M
52 Week Low
$1.75
52 Week High
$4.39
P/E
-5.71x
P/B
2.89x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$31.75M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.38
Operating Cash Flow
-$20M
Beta
0.38
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
DRTS Overview
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine DRTS's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
DRTS
Ranked#287 of 463
Ranked#287 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.61 | A | |
| $7.75 | A | |
| $16.85 | A |
Be the first to know about important DRTS news, forecast changes, insider trades & much more!
DRTS News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how DRTS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
DRTS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
DRTS is good value based on its book value relative to its share price (2.89x), compared to the US Biotechnology industry average (4.05x)
P/B vs Industry Valuation
DRTS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more DRTS due diligence checks available for Premium users.
Valuation
DRTS fair value
Fair Value of DRTS stock based on Discounted Cash Flow (DCF)
Price
$2.57
Fair Value
-$0.04
Undervalued by
6,047.28%
DRTS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
DRTS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-5.71x
Industry
-177.72x
Market
27.98x
DRTS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.89x
Industry
4.05x
DRTS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
DRTS's financial health
Profit margin
Revenue
$0.0
Net Income
-$9.5M
Profit Margin
0%
DRTS's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$86.2M
Liabilities
$23.5M
Debt to equity
0.38
DRTS's short-term assets ($64.23M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
DRTS's short-term assets ($64.23M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
DRTS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
DRTS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
DRTS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
DRTS vs Biotech Stocks
Alpha Tau Medical Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.